BAK1 (BCL2 Antagonist/Killer 1)

Gene expression profiling demonstrated ≥ twofold changes in 51 genes, including downregulation of BAK1 and TRAF3, and upregulation of BIRC2, BIRC3, BIRC6, CASP8, TNFRSF8, TNFRSF11, and BOK. Collectively, these findings indicate that SFV exerts significant antitumor effects in colorectal cancer models and support its potential as a promising anticancer agent, warranting further mechanistic and translational investigation.

Lenvatinib exhibits potent anti-CRC activity with minimal systemic toxicity. Its therapeutic effects are mediated through ERK pathway inactivation, suppression of anti-apoptotic proteins, and induction of caspase-dependent apoptosis.

The patient was initially treated with alectinib, but experienced rapid disease progression. After repeat genetic testing, therapy was switched to lorlatinib, which again resulted in early progression...To our knowledge, this is the first reported case of ivonescimab use in such a patient. This case offers a potential reference for the management of ALK fusion-positive lung adenocarcinoma resistant to ALK tyrosine kinase inhibitors (ALK-TKIs).

Receiver operating characteristic analyses demonstrated strong discrimination of IDH status (area under the curve ≥ 0.92 for key genes), whereas structure-guided docking nominated rational, multipathway combinations such as temozolomide + bortezomib, luteolin, or lovastatin. Collectively, this integrative omics approach reframes IDHmt GBM as a redox- and myeloid-driven suppressive ecosystem and provides a systems-level rationale for personalized, IDH-informed therapeutic strategies.

Activating this pathway in vivo regressed tumors in an mTORC2-dependent manner. Overall, our results identify a lytic cell death modality in response to the synergism of innate immune signaling and metabolic disruption.

RNF185 sustains mitochondrial homeostasis and ESCC cell survival by promoting BAK1 ubiquitination and limiting cGAS-STING-IRF3-mediated immune activation. Targeting RNF185 with small molecules like Honokiol may represent a promising therapeutic approach in ESCC.

This study indicated that different risk score groups exhibited different tumor mutation burden, immune microenvironment cell infiltration, immune response, differentially expressed genes, functional characteristics, correlations with immune checkpoint genes, and drug sensitivity. We established a novel ferroptosis-related oxidative stress gene-related model that possesses potential predictive value for prognosis of patients with LUAD, immunotherapy response, and chemotherapeutic drug sensitivity, and indicated its potential applicability in clinical practice.

In summary, our study indicated that miR-125b contributes to PDAC progression and gemcitabine resistance by downregulating BAK1. Targeting miR-125b might represent a promising therapeutic approach to overcome gemcitabine resistance in PDAC.

Mechanistically, we uncovered a novel regulatory axis wherein miR-483-3p directly modulates a BCLAF1/PUMA/BAK1 apoptotic signaling network, highlighting its critical role in maintaining PCa cell survival. Our findings provide novel insights into the complex regulatory role of miRNA in PCa progression and offer a potential therapeutic strategy for targeting miRNA-mediated pathways in metastatic disease.

We confirm a VK2-O dependent interaction between JAZF1 and Bak1 in live cells and unequivocally demonstrate that JAZF1 is essential for both the VK2ation of Bak1 and the subsequent VK2-induced apoptosis. These findings establish JAZF1 as an indispensable component of this newly characterized post-translational modification, substantially clarifying the molecular mechanism of VK2 function and advancing the development of VK2-based therapeutics.

Both univariate and multivariate Cox regression confirmed high PEA15 expression as an independent prognostic factor for recurrence in patients with stage I endometrioid adenocarcinoma.ConclusionsThe autophagy-related gene PEA15 is an independent prognostic biomarker in early-stage endometrial carcinoma, improving risk stratification between the MSI and CN-L subtypes. Immunohistochemical detection has clinical potential for molecular classification, offering opportunities for personalized postoperative management strategies.

In particular, BAK1 emerges as an independent prognostic marker with high diagnostic potential. These results offer promising insights into the development of gene-targeted therapies for OSCC, with BAK1 representing a potential therapeutic target.